InMed Pharmaceuticals, A Cannabinoid-Focused Company, Sponsored Benzinga's Cannabis Capital Conference

InMed Pharmaceuticals (NASDAQ:INM) is a global leader in researching, developing, manufacturing and commercializing rare cannabinoids and cannabinoid analogs. The company is focused on the therapeutic benefits of cannabinol (CBN) as a pipeline of cannabinoid-based drug candidates for the treatment of diseases with high unmet medical needs.

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.

InMed is a clinical-stage company with expertise in the development of biosynthesis, IP, manufacturing and GMP scale-up methodologies. In addition to their innovative research in CBN, InMed Pharmaceuticals is also widely known for its Foundations™ technology – a pediatric, patient-friendly cannabinoid delivery system.

Interested in learning more about the Benzinga Cannabis Capital Conference? Get more information here.

INMInMed Pharmaceuticals Inc

$0.8800-11.1%

Overview

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.